Ananda Device’s provides neuronal microphysiological systems to accelerate drug development by improving the standardization, precision, reproducibility, and physiological relevance of cellular assays. We offer customized services using our proprietary technology to de-risk and accelerate drug development. With our in vitro technology, we provide high-throughput analysis into neurodegenerative and neuromuscular diseases, including Alzheimer’s and Parkinson’s.
Atuka provides contract research and consultancy services for the biopharmaceutical industry with world-leading expertise in Parkinson’s disease and related neurological conditions. We provide cutting-edge, rodent and nonhuman primate models (toxin and molecular pathology driven) to evaluate efficacy and target engagement over a comprehensive range of symptomatic, motor (e.g. parkinsonism and dyskinesia), non-motor (e.g. cognition and impulse control) and disease-modification assays. Atuka also offers medicinal chemistry, DMPK and in-vivo imaging services to aid development of novel therapeutics.
NeuraLight is a digital health company advancing neurological evaluation and care. Our AI-driven platform integrates objective and sensitive digital markers to improve drug development, monitoring, and precision care for patients with neurological disorders – focusing on AD, PD, ALS, and MS.
Our platform includes proprietary Deep Learning algorithms that automatically extract a host of digital oculometric markers from facial videos captured on a standard webcam or smartphone. We are supported by a Scientific Advisory Board, including two Nobel Laureates, and have raised over $30M to date.
bit.bio combines the concepts of coding and biology to provide human cells for research, drug discovery and cell therapy, enabling a new generation of medicines. Our precision cell programming technology opti-oxTM enables deterministic activation of TF codes to program new cell identities including neurodegenerative disorders such as
Gaucher’s, Huntington’s and Parkinson’s disease. opti-ox reprogramming overcomes the ultimate barriers of cell manufacturing and enables precise, rapid and scalable generation of pure human cell types.
Olink Holding AB is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia.
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through the Company’s unparalleled sensitivity and flexibility. Its industry-leading Simoa® precision instruments, digital immunoassay technology, and CLIA-certified Accelerator laboratory have supported research that advances disease understanding, management and patient care in neurology, oncology, immunology, cardiology and infectious disease for nearly two decades.
StressMarq Biosciences is a bioreagents company offering antibodies, proteins, ELISA kits, and small molecules for the life sciences research sector. We have developed a range of fibrilized and oligomeric protein preparations for use in neurodegenerative disease research, including alpha synuclein, amyloid beta, tau, SOD1 and TTR. We are a world leader in the development and supply of fibrilized proteins (and their derivatives), protein oligomers, and antibodies to these constructs to assist researchers studying Alzheimer’s, Parkinson’s, and other neurodegenerative diseases.